Frans R J Verhey Selected Research

Institutionalization (Institutionalized Persons)

1/2019	The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study.
11/2016	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands.
1/2016	Prevalence and Correlates of Neuropsychiatric Symptoms in Nursing Home Patients With Young-Onset Dementia: The BEYOnD Study.
11/2013	The impact of early dementia diagnosis and intervention on informal caregivers.
4/2013	Predictors of the time to institutionalization in young- versus late-onset dementia: results from the Needs in Young Onset Dementia (NeedYD) study.
3/2010	Research protocol of the NeedYD-study (Needs in Young onset Dementia): a prospective cohort study on the needs and course of early onset dementia.
10/2009	Predictors of neuropsychiatric symptoms in nursing home patients: influence of gender and dementia severity.
12/2005	A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frans R J Verhey Research Topics

Disease

62	Dementia (Dementias) 01/2022 - 01/2003
36	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2005
28	Cognitive Dysfunction 10/2022 - 03/2002
7	Type 2 Diabetes Mellitus (MODY) 11/2021 - 08/2015
7	Atrophy 05/2016 - 03/2002
6	Inflammation (Inflammations) 01/2022 - 01/2016
5	Parkinson Disease (Parkinson's Disease) 01/2015 - 05/2006
4	Stroke (Strokes) 01/2022 - 05/2016
4	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2021 - 12/2014
4	Albuminuria 11/2021 - 01/2017
3	Hypertension (High Blood Pressure) 01/2020 - 02/2014
3	Frailty 01/2019 - 09/2014
3	Delirium 07/2018 - 02/2008
3	Depressive Disorder (Melancholia) 01/2017 - 01/2016
2	Prediabetic State (Prediabetes) 11/2021 - 11/2017
2	Amyloidosis 01/2021 - 01/2021
2	Insulin Resistance 11/2020 - 11/2017
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 08/2015
2	Cerebral Small Vessel Diseases 01/2020 - 01/2020
2	Frontotemporal Dementia (Semantic Dementia) 01/2017 - 07/2013
2	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/2017 - 01/2013
2	Psychotic Disorders (Schizoaffective Disorder) 01/2008 - 01/2007
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022
1	Glucose Intolerance 11/2021
1	Infarction (Infarctions) 01/2021
1	Memory Disorders (Memory Loss) 01/2021
1	Diabetes Mellitus 01/2020
1	Hyperemia 01/2020
1	Occupational Stress 08/2019
1	Brain Ischemia (Cerebral Ischemia) 01/2019
1	Cerebral Cortical Thinning 01/2018
1	Neurobehavioral Manifestations 01/2018
1	Hyperglycemia 11/2017
1	Mixed Dementias 01/2017
1	Obesity 01/2015
1	Coronary Disease (Coronary Heart Disease) 01/2015
1	Chronic Disease (Chronic Diseases) 12/2014
1	Lewy Body Disease (Lewy Body Dementia) 07/2013

Drug/Important Bio-Agent (IBA)

34	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2010
13	Amyloid (Amyloid Fibrils)IBA 10/2022 - 01/2013
13	Apolipoproteins E (ApoE)IBA 01/2022 - 03/2002
8	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2021 - 12/2011
6	ApolipoproteinsIBA 01/2022 - 03/2002
5	Glucose (Dextrose)FDA LinkGeneric 11/2021 - 01/2016
4	Biological ProductsIBA 12/2020 - 11/2005
3	Amyloid beta-PeptidesIBA 01/2021 - 02/2010
3	Antihypertensive Agents (Antihypertensives)IBA 11/2017 - 02/2014
3	Pharmaceutical PreparationsIBA 09/2012 - 09/2006
3	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2012 - 09/2006
2	flutemetamolIBA 01/2022 - 01/2017
2	ORALIT (ORS)IBA 01/2022 - 01/2021
2	CholesterolIBA 01/2022 - 01/2015
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2021 - 11/2017
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2021 - 01/2021
2	Indicators and Reagents (Reagents)IBA 01/2021 - 09/2014
2	MethoxyhydroxyphenylglycolIBA 01/2021 - 01/2021
2	Retinaldehyde (Retinal)IBA 01/2020 - 01/2020
2	LipidsIBA 01/2020 - 08/2015
2	A-factor (Streptomyces)IBA 01/2019 - 01/2003
2	Antipsychotic Agents (Antipsychotics)IBA 07/2018 - 01/2005
2	Insulin (Novolin)FDA Link 01/2018 - 05/2017
2	C-Reactive ProteinIBA 08/2016 - 01/2016
2	SolutionsIBA 01/2007 - 01/2007
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	antineoplaston A10 (A 10)IBA 01/2022
1	valylvaline (Val-Val)IBA 01/2022
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2022
1	3-hydroxykynurenineIBA 11/2021
1	xanthurenic acidIBA 11/2021
1	Kynurenic Acid (Kynurenate)IBA 11/2021
1	KynurenineIBA 11/2021
1	3-Hydroxyanthranilic AcidIBA 11/2021
1	Proteins (Proteins, Gene)FDA Link 12/2020
1	AlbuminsIBA 01/2020
1	InterleukinsIBA 01/2020
1	HDL CholesterolIBA 01/2020
1	SelectinsIBA 01/2020
1	E-SelectinIBA 01/2020
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2020
1	von Willebrand FactorIBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	Advanced Glycation End ProductsIBA 11/2017
1	Cystatin CIBA 01/2017
1	CreatinineIBA 01/2017
1	pentosidineIBA 01/2017
1	Syntex adjuvant formulationIBA 01/2017
1	Genetic Markers (Genetic Marker)IBA 05/2016
1	Biocompatible Materials (Biomaterials)IBA 12/2014

Therapy/Procedure

17	Home Nursing (Nursing, Home) 01/2021 - 01/2007
8	Institutionalization (Institutionalized Persons) 01/2019 - 12/2005
4	Activities of Daily Living (ADL) 01/2016 - 01/2008
2	Length of Stay 01/2021 - 01/2018
2	Therapeutics 12/2020 - 11/2013
2	Patient Care 01/2013 - 07/2012
1	Polypharmacy 01/2018
1	Stroke Rehabilitation 09/2017
1	Ambulatory Care (Outpatient Care) 05/2016
1	Self Care (Care, Self) 05/2016
1	Medical Day Care (Partial Hospitalization) 04/2016